Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042109 (urticaria)
 6,569 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In the course of treating twenty patients with acute urinary tract infections, the toxicity and efficacy of a small dosage regimen (50 mg p.o., t.i.d.) of minocycline were evaluated. No vestibular symptoms attributable to minocycline treatment were observed in any of the cases entered in this study. Adverse reactions included mild nausea in 1 case and urticaria in another case. Minocycline with this dosage regimen sterilized the urine of 90% of patients with acute urinary tract infections.
 ...
PMID:[Studies on small dosage regimen of minocycline in the treatment of urinary tract infections (author's transl)]. 51 1

Six adult dogs were given 5 mg of minocycline hydrochloride/kg of body weight IV. Pharmacokinetic evaluation of the serum drug concentration versus time data was performed, using the 2-compartment open model, the 3-compartment open model, and a noncompartmental model involving use of the statistical moment theory. All pharmacokinetic values except clearance were model independent. Minocycline half-life ranged between 6.48 and 7.24 hours; volume of distribution at steady state, between 1.859 +/- 0.368 and 2.001 +/- 0.468 L/kg; and clearance, between 3.195 +/- 0.618 and 3.424 +/- 0.684 ml/min/kg. These data are similar to those reported for oxytetracycline and indicate that the frequency of administration of the 2 tetracyclines should be the same. Three of the 6 dogs developed an adverse response to the IV injection of minocycline. Dog 1 developed urticaria and had initial serum drug concentrations of approximately 2 times the mean concentrations for the other dogs; values were not included in the pharmacokinetic analysis. Two other dogs had transient signs indicating cardiovascular depression or hypotension; their data were included. Due to the frequency of the unexpected reactions found in this study, it was concluded that dogs should not be given minocycline rapidly IV.
 ...
PMID:Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. 402 8

The purpose of the study presented herein was to determine the safety and efficacy of minocycline in patients whose acne vulgaris failed to respond adequately to tetracycline therapy and to confirm continued improvement in tetracycline-responsive patients when minocycline was substituted for tetracycline. Thirty-six acne vulgaris patients were given oral tetracycline (250 mg four times a day) for six weeks, followed by oral minocycline (50 mg three times a day) for six weeks. An analysis of the increase or decrease in total lesion counts obtained at biweekly intervals revealed that minocycline caused statically significant improvement both in patients who did not respond to tetracycline and in patients who did respond to tetracycline. Patients who did not respond to tetracycline therapy achieved a mean decrease of 54 percent in lesions after after six weeks of minocycline treatment. In tetracycline-responsive patients, six weeks' treatment with tetracycline caused a 33.5 percent mean decrease in the lesion count. When these patients received minocycline for a subsequent six-week period, the mean lesion count decreased by an additional 60 percent. Only one patient developed a side effect: severe itching and urticaria in a minocycline-treated subject warranted discontinuance of therapy. Minocycline was a safe and effective agent in the treatment of acne both in tetracycline-resistant and in tetracycline-responsive patients.
 ...
PMID:Minocycline treatment of tetracycline-resistant and tetracycline-responsive acne vulgaris. 645 86

Minocycline is widely used as a second-line antimicrobial for acne vulgaris. Some patients require doses of up to 200 mg daily to control their acne. To assess the long-term safety of minocycline when used at higher doses, 700 patients treated with minocycline at doses of 100 mg daily, 100/200 mg on alternate days and 200 mg daily, were recruited. The mean duration of treatment was 10.5 months. Side-effects were monitored and full blood count, blood urea, electrolytes and liver function tests were carried out on 200 of the 700 patients. Side-effects were recorded in 13.6%, and included vestibular disturbance, candida infection, gastrointestinal disturbance, cutaneous symptoms (pigmentation, pruritus, photosensitive rash and urticaria) and benign intracranial hypertension. Pigmentation was the only side-effect found to be significantly increased in patients taking higher doses of minocycline, as compared with lower doses (P < 0.01). All patients with pigmentation had taken a total cumulative dose of over 70 g. No significant abnormalities were found in any of the haematological and biochemical profiles. We conclude that minocycline, at doses of up to 200 mg/day, is safe, long-term, for acne, when such doses are clinically necessary.
 ...
PMID:Safety of long-term high-dose minocycline in the treatment of acne. 873 73

Minocycline is a semisynthetic tetracycline derivative that is often used in the treatment of acne vulgaris. To date, there has been only one case report of anaphylaxis to minocycline. We report here a case of anaphylaxis to oral minocycline. A 56-yr-old woman visited our hospital after three episodes of recurrent anaphylaxis. We performed an oral challenge test, the standard method for diagnosing drug allergies, with minocycline, one of the drugs she had taken previously. She developed urticaria, angioedema, nausea, vomiting, hypotension, and dyspnea within 4 min and was treated with intramuscular epinephrine, intravenous antihistamine and systemic corticosteroid. However, she presented similar symptoms at 50 min and at 110 min. In prescribing oral minocycline, physicians should consider the possibility of serious adverse reactions, such as anaphylaxis.
 ...
PMID:A case of anaphylaxis to oral minocycline. 2067 39